



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/662594
		Filing Date	9/15/2003
		First Named Inventor	Arnold
		Art Unit	1614
		Examiner Name	SPIVACK
Sheet 1	of 1	Attorney Docket Number	LPJ60XO

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PS	1	MARSH, BRODIE, GARRETT, TSAI-MORRIS & BRODIE, Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives, J. Med. Chem. 1985 Jun; 28(6):788-95.	
PS	2	BOOTH, Effects of the aromatization inhibitor androst-4-ene-3,6,17-trione on sexual differentiation induced by testosterone in the neonatally castrated rat, J Endocrinol. (1978).	
PS	3	SCIARRA & TOSCANO, Role of estrogens in human benign prostatic hyperplasia, Arch-Androl. 2000 May-Jun; 44(3):213-20.	
PS	4	VERMEULEN, KAUFMAN, GOEMAERE & VAN POTTELBERG, Estradiol in elderly men, Aging Male. 2002 Jun; 5(2):98-102.	

Examiner Signature	Phyllis Spivack	Date Considered	11/26/04
--------------------	-----------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.